Abstract:Objective. Tumor suppressor gene silencing via promoter hypermethylation is an important event in the pathogenesis of colorectal cancer (CRC). Some aberrant DNA hypermethylation has high tumor specificity, so it may contribute to early diagnosis of CRC. The objective of this study was to establish novel therapeutic and diagnostic strategies against CRC by identifying the novel methylation-related genes. Material and methods. Two microarray-based approaches were used to identify novel methylation-related genes in CRC. We identified methylation-sensitive genes in colon cancer cell line SW1116 by comparing differential expression genes after treatment with the methylation inhibiting drug, 5-aza-2'-deoxycitidine (5-aza-dC) using gene expression microarray. Promoter microarray analysis was performed to identify cancer-specific, methylation-related genes in two patients with CRC. Gene promoter methylation was identified by methylation-specific polymerase chain reaction (PCR) (MSP) in primary CRC. Gene expression level was assessed using real-time PCR analysis. Results. By using gene expression microarray, up-regulation of 253 genes was detected in the CRC cell line, SW1116, after treatment with 5-aza-dC. Of the 253 genes identified by gene expression microarray analysis, LRRC3B (leucine-rich repeat containing 3B) was isolated as a potential methylation-specific gene by promoter microarray analysis. MSP analysis showed frequent methylation of LRRC3B in primary CRC (24/31 cases, 77%). In addition, the LRRC3B methylation intensity was significantly higher in cancer tissues than in the corresponding non-cancerous tissues. Decreased LRRC3B expression (17/31, 55%) was observed in the cancer tissues by real-time PCR. Conclusions. LRRC3B may be a novel methylation-sensitive tumor suppressor gene in CRC. LRRC3B methylation has significant tumor specificity and may be a biomarker of CRC.

DNA Methylation of Tumor Suppressor Genes Located on Chromosome 3p in Non-small Cell Lung Cancer

Association of Abnormal Methylation of CpG Islands in Promoter Domains of Multiple Tumor Suppressor Genes with Non-Small Cell Lung Cancer

Methylation of Antioncogen at 3p in Non-Small Cell Lung Cancer

CpG Island Methylator Phenotype Involving Tumor Suppressor Genes Located on Chromosome 3p in Non-Small Cell Lung Cancer

Epigenetic Silencing of the 3p22 Tumor Suppressor DLEC1 by Promoter CpG Methylation in Non-Hodgkin and Hodgkin Lymphomas

Frequent Epigenetic Inactivation of Deleted in Lung and Esophageal Cancer 1 Gene by Promoter Methylation in Non–Small-Cell Lung Cancer

Aberrant Promoter Methylation of FBLN-3 Gene and Clinicopathological Significance in Non-Small Cell Lung Carcinoma.

Correlation between methylation status of tumor-related genes and mRNA transcriptional level in lung cancer cell lines.

Quantitative Assessment of Gene Promoter Methylation in Non-Small Cell Lung Cancer Using Methylation-Sensitive High-Resolution Melting.

CpG Island Methylator Phenotype Involving Chromosome 3p Confers an Increased Risk of Non-small Cell Lung Cancer

Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer

Infrequently Methylated Event At Sites-362 To-142 In The Promoter Of Tgf Beta R1 Gene In Non-Small Cell Lung Cancer

Infrequently methylated event at sites −362 to −142 in the promoter of TGFβR1 gene in non-small cell lung cancer

Aberrant Hypermethylation at Sites -86 to 226 of DAB2 Gene in Non-Small Cell Lung Cancer

Expression of ΔDNMT3B Variants and Its Association with Promoter Methylation of P16 and RASSF1A in Primary Non–Small Cell Lung Cancer

Epigenetic Silencing Oflrrc3bin Colorectal Cancer

Diagnostic Role of Wnt Pathway Gene Promoter Methylation in Non Small Cell Lung Cancer.

Application Of Runx3 Gene Promoter Methylation In The Diagnosis Of Non-Small Cell Lung Cancer

Analysis of Methylation Status of RASSF1A promoter Region and Transcription Level of Downstream Genes in Non-Small Cell Lung Cancer

[RUNX3 Promoter Hypermethylation and Prognosis of Early Surgically Resected Non-Small Cell Lung Cancers].

Highly Frequent Promoter Methylation and PIK3CA Amplification in Non-Small Cell Lung Cancer (NSCLC).